Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000586728 | SCV000699877 | uncertain significance | not provided | 2017-01-23 | criteria provided, single submitter | clinical testing | Variant summary: The PKHD1 c.778G>A (p.Glu260Lys) variant involves the alteration of a conserved nucleotide located at the end of exon 11. Exon 11 is involved in encoding immunoglobulin-like fold of the protein (via InterPro). 3/4 in silico tools predict a damaging outcome for this variant. In addition, 5/5 splice prediction tools predict a significant impact (i.e. abrogation or attenuation of utilization of consensus splice donor site) on normal splicing. Due to location of this variant, it may affect protein function by altering normal splicing. These predictions have yet to be confirmed by functional studies. This variant is absent in 121396 control chromosomes from ExAC. The variant of interest has not, to our knowledge, been reported in affected individuals via publications and/or reputable databases/clinical diagnostic laboratories. Therefore, due to the absence of clinical and functional data, this variant is currently classified as a VUS until additional data becomes available. |